




EXPERIMENTAL FINDINGS OF THE STUDY OF OZONE IN THE ANTITUMOR RESPONSE

MSc. JANET CEPERO CAÑAS

**DEPARTMENT OF PRECLINICAL RESEARCH
INSTITUTE OF ONCOLOGY AND RADIOBIOLOGY
HAVANA, CUBA**

E-MAIL: jcepero@infomed.sld.cu

WHAT IS CANCER ?



Progressive molecular changes, leading to cell clones arising with a malignant phenotype, characterized by developing adaptive survival advantage over normal cells, which proliferate chronically and result in clinically detectable malignant tumors.

Cancer Progression

Evade molecular controls of cell growth, induction of senescence and programmed cell death.

The current knowledge about the origin and evolution of malignancies should contribute to the design of strategies for prevention, early diagnosis and treatment of advanced disease

THE ESCAPE TO THIS REGULATION INDUCE THE SUSTAINED PROLIFERATION OF TUMORS

Signals factors growth




Cdk/C



Tumor suppressor genes

THIS IS CONSIDERED THE INITIAL EVENT OF TUMORIGENESIS

PLASTICITY OF CELL POPULATIONS ORGANIZED HIERARCHICALLY




- An emerging concept states that Cancer Stem Cells (CSC), key in cancer initiation and metastasis cells, arise when "transit amplifying" cells containing mutations are de-differentiate and enter a state of stem cell
- This model contrasts with the notion that CSC are derived from neoplastic transformation of normal cells mothers.

Cancer Discov. Vol 5 No 1, 22-24, 2015

Understand cancer as a genetic disease that generates a systemic inflammation that allows the metastatic spread of the disease.

HALLMARKS OF CANCER



Deregulation of cellular energy
(metabolic Reprogramming)

Self-sufficiency in growth
signals

Insensitivity to growth
suppressive signals

Unlimited replicative potential

Sustained angiogenesis

Tissue invasion and metastasis


Evasion of apoptosis

Promoting inflammation

Immunosuppressant
environment

Inflammation and genetic instability: enabling conditions

Reactive oxygen species (ROS) are involved in a diversity of important phenomena in the process of tumor development




MECHANISMS ASSOCIATED TO CARCINOGENESIS MEDIATED BY ROS

TUMOR MICROENVIRONMENT (TME)


Essential elements:

- Tumor cells
- Fibroblasts (CAFs)
- Blood vasculature
 - Endothelial cells
 - Pericytes
 - Platelets
- Extracellular matrix (ECM)
- Immune cells
 - Myeloid cell
 - Lymphocyte
- Factors secreted





Maintains the cellular redox balance



OZONE



Increases oxygen metabolism

(O₃ increases oxygenation in hypoxic tumors).

Tumor hypoxia increase resistance to radiotherapy and chemotherapy.


Influences in the synthesis / release of eicosanoids

Immunological regulator



Ozone may induce an adaptation to oxidative stress or an oxidative preconditioning, that under controlled doses, may stimulate the endogenous antioxidant mechanism, preparing the host to face physiopathological conditions mediated by reactive oxygen species

DEMONSTRATED PROTECTION MEDIATED BY O_3 / O_2



**LINK BETWEEN THE TISSULAR DAMAGE,
INDUCED CHEMICALLY OR SURGICALLY, AND THE CANCER**

GENERAL AIM

To determine the possible effects of ozone therapy in some experimental models of malignant tumors in mice.

SPECIFIC AIMS

1. To evaluate the reiterated toxicity of the ozone therapy using different applications.
2. To evaluate the effect of ozone therapy on multiplicity of tumors.
3. To evaluate the effect of the ozone oxidative-preconditioning in tumor development.



MATERIALS AND METHODS

OZONE GENERATOR OZOMED MOD 01

1. Reiterated Toxicity Assay:

Mice: NMRI males and females, 20-25 g.

Administration schedule:

O₃/O₂ during 15 days, rectal and intraperitoneal applications.

Rectal concentrations: 11, 35 y 71 mg/L,

Volume: 5, 40 y 80 mL/Kg in each case.

Intraperitoneal concentrations: 11, 20 y 35 mg/L, Vol 1 mL



MATERIALS AND METHODS

OZONE GENERATOR OZOMED MOD 01

2. Evaluation of tumor multiplicity using different ozone concentrations.

Mice: NMRI and B₆D₂F₁ males, 18-20 g

Schedule: O₃/O₂ rectal application
cycle of 12 days

Concentrations: 19, 26 y 42 mg/(n=10)
(1 mL in each case)

Tumors:

- Erlich Ascitic Tumor
- Sarcoma 37

(1 x 10⁶ cells implanted by
ocular plexus)

**The hematogenic
dissemination of the
neoplastic cells present
in the lung was
evaluated.**



MATERIALS AND METHODS

OZONE GENERATOR OZOMED MOD 01



3. Effects of ozone oxidative-preconditioning in tumor development.

Mice: B₆D₂F₁ males, 18-20 g

Schedule: 15 sessions daily O₃/O₂

Pre- treatment, intraperitoneal application.

Concentrations: 4, 11, 20 y 35 mg/L
volume 80 mL/Kg in each case. (n=10)


Tumor: Lewis Lung Carcinoma.
1 x 10⁶ cells

(0.25 mL subcutaneous,

24 h after the ozone treatment)

Tumoral volume calculation:


$V \text{ (mm}^3\text{)} = a^2 \times L/2$
(a- wide, L- large)



Animal weights and tumor volume measurements.

Toxicity assays in mice

Table 1. Results of body weight in NMRI mice using rectal ozone application.



Body weight gained during rectal ozone treatment was less in groups treated with higher concentrations, but there was not significant differences between groups at the end of the assay.

Table 2. Relative weights (%) of the organs in NMRI mice using rectal ozone application

Groups		Spleen	Liver	Heart	Lung
Control		0.58	6.17	0.72	0.60
O₃/O₂	11 mg/L	0.74	5.55	0.64	0.63
	35 mg/L	0.54	5.69	0.62	0.62
	71 mg/L	0.52	5.39	0.54	0.64

These results are with the highest volume (80 mL/Kg) for all the ozone concentrations studied.

The pathology study of the organs did not show toxicity alterations in the groups at the maximum doses of ozone treatment.

Table 3. Hematological parameters evaluated in NMRI mice using rectal ozone application.

Time (days)	Control	O ₃ /O ₂		
		c=11 mg/L	c= 35 mg/L	c=71 mg/L
Beginning (t=0)				
Hematocrite	0.42 ±0.029	0.43 ±0.057	0.51 ±0.012	0.47 ±0.064
Leucocytes(x 10 ⁹)	5.13 ±0.15	4.23 ±0.12	4.23 ±0.12	5.13 ±0.15
Polymorph	25.0 ±1	18.33 ±8.50	16.33 ±6.11	16.67 ±5.51
Lymphocytes	75.0 ±1	81.67 ±8.50	83.67 ±6.11	83.33 ±5.51
End of treatment (t=15)				
Hematocrite	0.52 ±0.029	0.53 ±0.029	0.50 ±0	0.49 ±0.036
Leucocytes(x 10 ⁹)	6.17 ±0.12	7.17 ±0.12	9.13 ±0.15	7.20 ±0.26
Polymorpho	25 ±5	27 ±3.61	20 ±2	39.67 ±1.53
Lymphocytes	75 ±5	73 ±3.61	80 ±2	60.33 ±1.53

These results are with the highest volume (80 mL/Kg) for all the ozone concentrations studied.

Table 4. Results of body weight in NMRI mice (both sex) using intraperitoneal ozone application.





Table 5. Relative weights (%) of the organs in NMRI mice (both sex) by intraperitoneal ozone application

Groups		Spleen		Liver		Heart		Lung		Kidney	
		F	M	F	M	F	M	F	M	F	M
Control		0.69	0.53	6.57	7.01	0.55	0.51	0.88	0.75	1.27	1.61
O ₃ /O ₂ (mg/L)	11	0.68	0.68	6.50	6.54	0.58	0.58	0.98	0.76	1.28	1.61
	20	0.81	0.77	6.81	7.34	0.56	0.66	1.08	0.84	1.33	1.66
	35	0.77	0.67	7.08	5.23	0.79	0.43	1.19	0.89	1.99	1.09

Table 6. Hematological parameters evaluated in NMRI mice (both sex) by intraperitoneal ozone application.

Time (days)	Control		O ₃ /O ₂					
			c=11 mg/L		c= 20 mg/L		c=35 mg/L	
Beginning (t=0)	F	M	F	M	F	M	F	M
Hematocrite	0.51	0.49	0.51	0.49	0.46	0.47	0.46	0.42
Leucocytes (x 10 ⁹)	7.4	7.4	8.13	<u>4.23</u>	7.93	8.16	8.46	8.3
Polymorph	27.0	22.3	13.7	16.33	29	14.7	31.33	17.33
Lymphocytes	71.6	76.3	85.7	83.67	70.3	85	59.38	82.7
End of treatment (t=15)								
Hematocrite	0.6	0.52	0.52	0.45	0.51	0.51	0.52	0.49
Leucocytes (x 10 ⁹)	8.23	9.13	8.7	7.85	9.23	7.8	8.9	9.26
Polymorph	11.3	20.3	12.7	28.5	21.3	18.33	10.7	14.66
Lymphocytes	86.6	77.6	86.6	70	77	80.7	88.3	83.65

The hematogenic dissemination of the Ehrlich Ascitic tumor in mice lung using rectal ozone application

Number of cells/mice




Figure 1. Tumor multiplicity in mice inoculated by the ocular plexus with 1 million cells of Ehrlich Ascitic Tumor, using 1 mL of ozone at different concentrations (19, 26 and 42 mg/L) by rectal application, during 12 sessions after the inoculation. Data are mean \pm SEM. Means having different letters indicate significant difference ($p < 0.05$) between groups.

The hematogenic dissemination of the Sarcoma-37 tumor in mice lung using rectal ozone application.

Number of cells/mice




Figure 2. Tumor multiplicity in mice inoculated by the ocular plexus with 1 million cells of Sarcoma-37, using different ozone concentrations (26 and 42 mg/L) by rectal application, during 12 sessions after the inoculation. Data are mean \pm SEM. Means having different letters indicate significant difference ($p < 0.05$) between groups.

Tumor development kinetics of Lewis' Lung carcinoma with ozone oxidative-preconditioning by intraperitoneal application




Figure 3. A significant delay ($p \leq 0.05$) in the beginning kinetics of Lewis' lung carcinoma was observed in ozone treated groups respect control group. Ozone was applied to mice intraperitoneally at concentrations of 4, 11, 20, 35 mg/L and a volume of 80 ml/kg, daily for 15 days. Twenty four hours after the last ozone treatment, animals were inoculated with 1 million cells of tumor by subcutaneous way (0.25 mL).

Tumor volume increase of Lewis' lung carcinoma with ozone oxidative-preconditioning by intraperitoneal application.





Figure 4. A significant delay ($p \leq 0.05$) in tumor volume increase was observed in ozone treated groups respect control group. Ozone was applied to mice intraperitoneally at concentrations of 4, 11, 20, 35 mg/L and a volume of 80 ml/kg, daily for 15 days. Twenty four hours after the last ozone treatment, animals were inoculated with 1 million cells of the Lewis' lung carcinoma by subcutaneous way (0.25 mL).



Hidalgo, J. Universidad de Granada, 2014

Effect on tumor volume of different treatments by IP route (O₃ 50 mg/L, Doxorubicin 2 mg/Kg and its combination), post-inoculation of lung carcinoma 3LL (5×10^5 cells),



The intraperitoneal treatment with ozone induced reduction of tumor volume in treated animals compared to the control, but there was not a better response of the combination compared to the treatment with doxorubicin

Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas

Siegfried Schulz¹, Ulrich Häussler², Robert Mandic², Johannes T. Heverhagen³, Andreas Neubauer⁴, Anja A. Dünne², Jochen A. Werner², Eberhard Weihe⁵ and Michael Bette^{5*}

¹Veterinary Services and Laboratory Animal Medicine, Philipps University Marburg, Germany

²Department of Otolaryngology, Head and Neck Surgery, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany

³Department of Diagnostic Radiology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany

⁴Department of Haematology, Oncology and Immunology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany

⁵Department of Molecular Neuroscience, Institute of Anatomy and Cell Biology, Philipps University Marburg, Germany

Head and neck squamous cell carcinomas (HNSCC) represent a group of metastasizing tumors with a high mortality rate in man and animals. Since the biomolecule ozone was found to inhibit growth of various carcinoma cells *in vitro* we here applied the highly aggressive and lethal VX2 carcinoma HNSCC tumor model of the New Zealand White rabbit to test whether ozone exerts anti-tumorous effects *in vivo*. Therapeutic insufflation of medical ozone/oxygen (O₃/O₂) gas mixture into the peritoneum (O₃/O₂-pneumoperitoneum) at an advanced stage of tumor disease led to a survival rate of 7/14 rabbits. Six of the seven surviving rabbits presented full tumor regression and the absence of local or distant lung metastases. Insufflation of pure oxygen (O₂) resulted in a survival rate of 3/13 animals accompanied by full tumor remission in 2 of the 3 surviving animals. Of the 14 sham-treated animals only 1 had spontaneous tumor remission and survived. No adverse effects or changes in standard blood parameters were observed after repeated intraperitoneal insufflations of the O₃/O₂ or O₂ gas. Animals with O₃/O₂-induced tumor eradication developed tolerance against reimplantation of the VX2 tumor. This could be reversed by immune suppression with a combination of dexamethasone and cyclosporin A suggesting an antitumorous effect of O₃/O₂-mediated activation of the body's own immunosurveillance. Although the exact mechanisms of action are still unclear the present data point to O₃/O₂-pneumoperitoneum as a promising new strategy in anticancer therapy.




FIGURE 3 – Growth and development of the VX2 tumor cells in the right ear of NZW rabbits after inoculation. Panel (a) shows representative macroscopic views of a solid auricular VX2 tumor in the right ear of a rabbit on Day 14 after tumor cell inoculation and different stages of remission after O₃/O₂ therapy (O₃/O₂-pneumoperitoneum). The spontaneous tumor remission observed in one sham-treated rabbit and the 2 remissions after O₂ gas insufflation were similar (macroscopic views are not shown). Note, that only a small scar of the remitted auricular tumor remained on Day 90, the end point of our observation period. In sharp contrast, in rabbits that succumbed to tumor progression the auricular tumor continued growing resulting in severe ulcerations associated with massive bleeding and onset of local infections introducing the final stage of this tumor disease (b, representative stages of the same rabbit are shown). Depicted are tumor stages on Days 14, 27, 35, and at the end of the observation period (90 days or 42 days in case of death).

Tumor development

C

day 14

day 27

day 35


final outcome

O₃/O₂ cured

cured day 90

sham dead

dead day 42





CONCLUSIONS

- ✓ **The ozonotherapy by rectal and intraperitoneal application did not induce toxicity manifestations in the reiterated assay in mice.**
- ✓ **There was obtained a significant decrease in the number of lung metastasis in Ascitic Erlich Tumor and Sarcoma 37 by rectal ozone application at the used doses.**
- ✓ **Ozone pre-conditioning by intraperitoneal application produced a retard effect in the beginning kinetics of Lewis' lung carcinoma and in tumor volume increase.**

CONCLUSIONS


- ✓ **In spite of the positive ozone biological effects and its potential usefulness observed in this experimental tumors, further preclinical researches are necessary to be performed, in order to reaffirm the ozone therapy as complementary therapy for cancer.**

NEW TRENDS

- To move to more advanced stages of the disease.
- Inserted in initial treatment regimens in combination with standard therapies (chemo and radiation treatments)
- Using combinations of different forms of therapy

Expectations of therapeutic combinations in Cancer

Improving Survival with Combination Therapy



INOR



“The better strategies for cancer treatment could be based on the combination of complementary therapies with different mechanisms of action and acceptable toxicity”



**INSTITUTE OF ONCOLOGY
AND RADIOBIOLOGY OF
CUBA.**